Glaukos Corporation (GKOS) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $239.19 (-1.35%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 18, 2026 | David Saxon | Needham | $127.00 | -46.9% |
| Nov 10, 2025 | Danielle Antalffy | UBS | $140.00 | -41.5% |
| Oct 30, 2025 | Richard Newitter | Truist Financial | $120.00 | -49.8% |
| Oct 30, 2025 | David Saxon | Needham | $117.00 | -51.1% |
| Oct 27, 2025 | Thomas Stephan | Stifel Nicolaus | $115.00 | -51.9% |
| Oct 13, 2025 | Ryan Zimmerman | BTIG | $104.00 | -56.5% |
| May 1, 2025 | Richard Newitter | Truist Financial | $135.00 | -43.6% |
| Dec 31, 2024 | Thomas Stephan | Stifel Nicolaus | $175.00 | -26.8% |
| Dec 18, 2024 | Richard Newitter | Truist Financial | $185.00 | -22.7% |
| Dec 2, 2024 | Thomas Stephan | Stifel Nicolaus | $153.00 | -36.0% |
| Dec 2, 2024 | Patrick Wood | Morgan Stanley | $120.00 | -49.8% |
| Nov 5, 2024 | David Saxon | Needham | $149.00 | -37.7% |
| Nov 5, 2024 | Ryan Zimmerman | BTIG | $140.00 | -41.5% |
| Oct 29, 2024 | Michael Sarcone | Jefferies | $155.00 | -35.2% |
| Oct 21, 2024 | Samuel Brodovsky | Truist Financial | $152.00 | -36.5% |
| Oct 17, 2024 | Matt O'Brien | Piper Sandler | $140.00 | -41.5% |
| Sep 23, 2024 | Ryan Zimmerman | BTIG | $139.00 | -41.9% |
| Sep 3, 2024 | Thomas Stephan | Stifel Nicolaus | $145.00 | -39.4% |
| Jun 5, 2024 | Thomas Stephan | Stifel Nicolaus | $130.00 | -45.7% |
| Jun 3, 2024 | Larry Biegelsen | Wells Fargo | $120.00 | -49.8% |
Top Analysts Covering GKOS
GKOS vs Sector & Market
| Metric | GKOS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.03 | 2.25 | 2.41 |
| Analyst Count | 31 | 8 | 19 |
| Target Upside | -8.6% | +153002.0% | +21.5% |
| P/E Ratio | -36.65 | 3.50 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $610M | $613M | $616M | 9 |
| 2027-03-31 | $167M | $171M | $174M | 4 |
| 2027-06-30 | $182M | $187M | $190M | 6 |
| 2027-09-30 | $191M | $195M | $198M | 4 |
| 2027-12-31 | $206M | $211M | $214M | 7 |
| 2028-03-31 | $177M | $181M | $184M | 3 |
| 2028-06-30 | $195M | $199M | $202M | 5 |
| 2028-09-30 | $207M | $212M | $215M | 3 |
| 2028-12-31 | $224M | $229M | $233M | 6 |
| 2029-12-31 | $1.25B | $1.29B | $1.33B | 5 |
| 2030-12-31 | $1.46B | $1.51B | $1.56B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.68 | $-0.54 | $-0.39 | 9 |
| 2027-03-31 | $0.01 | $0.01 | $0.01 | 3 |
| 2027-06-30 | $0.08 | $0.08 | $0.09 | 3 |
| 2027-09-30 | $0.12 | $0.13 | $0.13 | 4 |
| 2027-12-31 | $0.17 | $0.18 | $0.18 | 3 |
| 2028-03-31 | $0.08 | $0.08 | $0.08 | 4 |
| 2028-06-30 | $0.13 | $0.13 | $0.13 | 4 |
| 2028-09-30 | $0.24 | $0.25 | $0.26 | 6 |
| 2028-12-31 | $0.32 | $0.33 | $0.34 | 4 |
| 2029-12-31 | $2.51 | $2.62 | $2.71 | 2 |
| 2030-12-31 | $4.14 | $4.33 | $4.49 | 5 |
Frequently Asked Questions
What is the analyst consensus for GKOS?
The consensus among 31 analysts covering Glaukos Corporation (GKOS) is Buy with an average price target of $192.89.
What is the highest price target for GKOS?
The highest price target for GKOS is $185.00, set by Richard Newitter at Truist Financial on 2024-12-18.
What is the lowest price target for GKOS?
The lowest price target for GKOS is $66.00, set by Ryan Zimmerman at BTIG on 2022-04-21.
How many analysts cover GKOS?
31 analysts have issued ratings for Glaukos Corporation in the past 12 months.
Is GKOS a buy or sell right now?
Based on 31 analyst ratings, GKOS has a consensus rating of Buy (2.03/5) with a -8.6% upside to the consensus target of $192.89.
What are the earnings estimates for GKOS?
Analysts estimate GKOS will report EPS of $-0.54 for the period ending 2026-12-31, with revenue estimated at $613M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.